UltiMAb Publications

Chen, J., M. Trounstine, F. W. Alt, F. Young, C. Kurahara, J. Loring, D. Huszar. "Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the J_H locus." lnternational Immunology 5 (1993): 647-656.

Chen, J., M. Trounstine, C. Kurahara, F. Young, C. Kuo, Y. Xu, J. Loring, F. W. Alt, D. Huszar. "B cell development in mice that lack one or both immunoglobulin k light chain genes." The EMBO Journal 12 (1993): 821-830.

Choi, T., P. Hollenbach, B. Pearson, R. Ueda, G. Weddell, C. Kurahara, C. Woodhouse, R. Kay, J. Loring. "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome." Nature Genetics 4 (1993): 117-123.

Fishwild, D., S. O'Donnell, T. Bengoechea, D. Hudson, F. Harding, S. Bernhard, D. Jones, R.M. Kay, K. Higgins, S. Schramm, N. Lonberg. "High-avidity human IgG_K monoclonal antibodies from a novel strain of minilocus transgenic mice." Nature Biotechnology 14 (1996): 845-851.

Harding, F., N. Lonberg. "Class Switching in Human Immunoglobulin Transgenic Mice." Annals of the New York Academy of Sciences (1995).

Lonberg, N., L. Taylor, F. Harding, M. Trounstine, K. Higgins, S. Schramm, C. Kuo, R. Mashayekh, K. Wymore, J. McCabe, D. Munoz-O'Regan, S. O'Donnell, E.S.G. Lapachet, T. Bengoechea, D. Fishwild, C. Carmack, R. Kay, D. Huszar. "Antigen-specific human antibodies from mice comprising four distinct genetic modifications." Nature 368 (1994): 856-859.

Lonberg, N. "Transgenic Approaches to Human Monoclonal Antibodies." Handbook of Experimental Pharmacology 113 (1994): 49-101.

Lonberg, N., D. Huszar. "Human Antibodies from Transgenic Mice." Internal Review of Immunology 13 (1995): 65-93.

Morrison, S. "Success in specification." Nature 368 (1994): 812-813

Neuberger, M. "Generating high-avidity human Mabs in mice." Nature Biotechnology 14 (1996): 826.

Taylor, L., C. Carmack, S. Schramm, R. Mashayekh, K. Higgins, C. Kuo, C. Woodhouse, R. Kay, N. Lonberg. "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins." Nucleic Acids Research 20 (1992): 6287-6295.

Taylor, L., C. Carmack, D. Huszar, K. Higgins, R. Mashayekh, G. Sequar, S. Schramm, C. Kuo, S. O'Donnell, R. Kay, C. Woodhouse, N. Lonberg. "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM." lnternational Immunology 6 (1994): 579-591.

Tomizuka, K., H. Yoshida, H. Uejima, H. Kugoh, K. Sato, A. Ohguma, M. Hayasaka, K. Hanaoka, M. Oshimura, I. Ishida. "Functional expression and germline transmission of a human chromosome fragment in chimaeric mice." Nature Genetics 16(2) (1997): 133-43.

Tomizuka, K., T. Shinohara, H. Yoshida, H. Uejima, A. Ohguma, S. Tanaka, K. Sato, M. Oshimura, I. Ishida. "Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and k loci and expression of fully human antibodies." Proceedings of the National Academy of Sciences USA 97(2) (2000): 722-727.

Tuaillon, N., L. Taylor, N. Lonberg, P. Tucker, J.D. Capra. "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: Gene-segment use in m and g transcripts." Proceedings of the National Academy of Sciences USA 90 (1993): 3720-3724.

Tuaillon, N., A. Miller, N. Lonberg, P. Tucker, J. D. Capra. "Biased Utilization of D_HQ52 and J_H4 Gene Segments in a Human Ig Transgenic Minilocus Is Independent of Antigenic Selection." Journal of Immunology 152 (1994): 2912-2920.

Monoclonal Publications

Deo, Y.M., K. Sundarapandiyan, T. Keler, R.F. Graziano. "Bispecific molecules directed to the Fc receptor for IgA (FcaRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood." Journal of Immunology 160 (1998): 1677-1686.

Drakeman, D., M.W. Fanger, P.K. Wallace. "Bispecific antibodies for the treatment of tumours and infectious diseases." Expert Opinion on Investigational Drugs 6 (1997): 1169-1178.

Goldstein, J., R.F. Graziano, K. Sundarapandiyan, C. Somasundaram, Deo, Y.M. "Cytolytic and cytostatic properties of an anti-human FcgRI (CD64) x epidermal growth factor bispecific fusion protein." Journal of Immunology 158 (1997): 872-879.

Graziano, R.F., P.R. Tempest, P. White, T. Keler, Y.M. Deo, H. Ghebremariam, K. Coleman, L.C. Pfferkorn, M.W. Fanger, P.M. Guyre. "Construction and characterization of a humanized anti-g-immunoglobulin receptor type I (FcgRI) monoclonal antibody." Journal of Immunology 155 (1995): 4996-5002.

Graziano, R.F., J. Goldstein, K. Sundrapandiyan, C. Somasundaram, T. Keler, Y.M.Deo. "Targeting tumor cell destruction with CD64-directed bispecific fusion proteins." Cancer Immunology Immunotherapy 45 (1997): 124-127.

Guyre, P.M., R.F. Graziano, B.A. Vance, P.M. Morganelli, M.W. Fanger. "Monoclonal antibodies that bind to distinct epitopes on FcgRI are able to trigger receptor function." Journal of Immunology 143 (1989): 1650-1655.

Russoniello, C., C. Somasundaram, J. Schlom, Y.M. Deo, T. Keler. "Characterization of a novel bispecific antibody that mediates Fcg receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells." Clinical Cancer Research 4 (1998): 2237-2243.

Valerius T., B. Stockmeyer, A.B. van Spriel, R.F. Graziano, I.E. van den Herik-Oudijk, R. Repp, Y.M. Deo, J. Lund, J.R. Kalden, M. Gramatzki, J.G.J. van de Winkel. "FcaRI (CD89) as a novel trigger molecule for bispecific antibody therapy." Blood 90 (1997): 4485-4492.

van de Winkel, J. G. J., B. Bast, G.C. de Gast. "Immunotherapeutic potential of bispecific antibodies." Immunology Today 18 (1997): 562-564.

MDX-010

Thompson, C.B., J.P. Allison. "The emerging role of CTLA-4 as an immune attenuator." Immunity 7(4) (1997):445-450.

Leach, D.R., M.F. Krummel, J.P. Allison. "Enhancement of antitumor immunity by CTLA-4 blockade." Science 271(5256) (1996):1734-1736.

Miscellaneous

Curnow, R.T. "Clinical experience with CD64-directed immunotherapy. An overview." Cancer Immunology and Immunotherapy 92 (1997): 210-215.

Deo, Y.M., R.F. Graziano, R. Repp, J.G.J. van de Winkel. "Clinical significance of IgG Fc receptors and FcgR-directed immunotherapies." Immunology Today 18 (1997): 126-135.

Eisenhut, M., W.D. Lehmann, W. Becker, T. Behr, H. Elser, A. Steinstrasser, R. Baum, T. Valerius, R. Repp, Y.M. Deo. "Bifunctional NHS-BAT ester for antibody conjugation and stable ^99mTc labeling: conjugation chemistry, immunoreactivity and kit formulation." (1995) Journal of Nuclear Medicine. 37, 362.

Elsässer, D., T. Valerius, R. Repp, G.J. Weiner, Y.M. Deo, J.R. Kalden, J.G.J. van de Winkel, G.T. Stevenson, M.J. Glennie, M. Gramatzki. "HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor." Blood. 87(9) (1996): 3803-3812.

Fanger, N.A., K. Wardwell, L. Shen, T.F. Tedder, P.M. Guyre. "Type I (CD64) and Type II (CD32) Fcg Receptor-Mediated Phagocytosis by Human Blood Dendritic Cells." Journal of Immunology 157 (1996): 541-548.

Gosselin, E.J., K. Wardwell, D.R. Gosselin, N. Alter, J.L. Fisher, P.M. Guyre. "Enhanced antigen presentation using human Fcg receptor (monocyte/macrophage)-specific immunogens." Journal of Immunology 149 (1992): 3477-3481.

Heijnen, I., M.J. van Vugt, N.A. Fanger, R.F. Graziano, T.P. de Wit, F.M. Hofhuis, P.M. Guyre, P.J. Capel, J.S. Verbeek, J.G. van de Winkel. "Antigen Targeting to Myeloid-specific Human FcgRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice." Journal of Clinical Investigation 97 (1996): 331-338.

Keler, T., H. Li, M.W. Cloyd, L.A. Vitale, Y.M. Deo. "Development of T-cell lines expressing functional HIV-1 envelope glycoproteins for evaluation of immune responses in HIV-infected individuals." Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13 (1996): 117-126.

Keler, T., P.K. Wallace, L.A. Vitale, C. Russoniello, K. Sundarapandiyan, R.F. Graziano, Y.M. Deo. "Differential effect of cytokine treatment on FcaRI and FcgRI mediated tumorcytotoxicity by mionocyte." Journal of Immunology 164 (2000): 5746-5752.

Keler, T., P.M. Guyre, L.A. Vitale, K. Sundarapandiyan, Jan G.J. van de Winkel, Y.M. Deo, R.F. Graziano. "Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice." Journal of Immunology 165 (2000): 6738-6742.

Liu, C., J. Goldstein, R.F. Graziano, J. He, J.K. O'Shea, Y.M. Deo, P.M. Guyre. "FcgRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes." Journal of Clinical Investigation 98(9) (1996): 2001-2007.

Michon, J., S. Moutel, J. Barbet, J.L. Romet-Lemonne, Y.M. Deo, W.H. Fridman, J.L. Teillaud. "In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulated factor-treated cancer patients using an anti disialoganglioside/anti-FcgRI (CD64) bispecific antibody." Blood 86 (1995): 1124-1130.

Park, R.K., D. Kayvon, Y.M. Deo, Y. Liu, D.L. Durden. "Role of Src in the modulation of multiple adaptor proteins in FcaRI oxidant signaling." Blood 94 (1999): 2112-2120

Rieser, C., R. Ramoner, G.Böck, Y.M. Deo, L. Höltl, G. Bartsch, M. Thurnher. "Human monocyte-derived dendritic cells produce macrophage colony-stimulating factor: enhancement of c-fms expression by interleukin-10." European Journal of Immunology 28 (1998): 2283-2288.

Somasundaram, C., K. Sundarapandiyan, T. Keler, Y.M. Deo, R.F. Graziano. "Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells." Human Antibodies 9 (1999):47-54.

Thepen, T., A.J. van Vuuren, R.C. Kiekens, C.A. Damen, W.C. Vooijs, J.G. van De Winkel. "Resolution of cutaneous inflammation after local elimination of macrophages" Nature Biotechnology 18 (2000): 48-51.